#4-48E. mRNA vs Standard: Redefining Seasonal Influenza Prevention in Older Adults (NEJM, 2026)

Can we achieve better protection against seasonal influenza in our older adult patients compared to traditional egg-based vaccines? In this phase 3, double-blind, randomized controlled trial involving over 40,000 adults aged 50 and older, researchers evaluated the efficacy and safety of mRNA-1010, an investigational trivalent mRNA seasonal influenza vaccine, against a licensed standard-dose comparator. The study demonstrated that mRNA-1010 achieved a superior relative vaccine efficacy of 26.6% against RT-PCR-confirmed influenza-like illness, showcasing the potential of the rapidly updatable mRNA platform to overcome antigenic mismatch issues common in traditional egg-based production. However, when critically appraising these results, clinicians must weigh this enhanced efficacy against a notably higher incidence of solicited mild-to-moderate reactogenicity, such as injection-site pain and fatigue, compared to standard-dose vaccines. For practicing physicians, this represents a significant advancement in our preventive arsenal, offering a more robust vaccination strategy for vulnerable older populations while underscoring the vital need for proactive patient counseling regarding expected, transient side effects.

Citation: Leroux-Roels I, Huang G, et al. Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults. New England Journal of Medicine. 2026. DOI: 10.1056/NEJMoa2516491

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.